Rafferty Asset Management, LLC Neurocrine Biosciences Inc Transaction History

Rafferty Asset Management, LLC

$29.7 Billion
Q3 2025

A detailed history of Rafferty Asset Management, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 58,701 shares of NBIX stock, worth $8.5 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

58,701

Previous 79,146 25.83%

Holding current value

$8.5 Million

Previous $9.95 Million 17.16%

% of portfolio

0.03%

Previous 0.03%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	SELL	$123.98 - $146.67 $2.53 Million - $3 Million	-20,445 Reduced 25.83%	58,701 $8.24 Million
Q2 2025 Aug 14, 2025	SELL	$87.54 - $128.18 $1.9 Million - $2.78 Million	-21,661 Reduced 21.49%	79,146 $9.95 Million
Q1 2025 May 14, 2025	SELL	$107.22 - $153.29 $665,192 - $951,011	-6,204 Reduced 5.8%	100,807 $11.1 Million
Q4 2024 Feb 14, 2025	SELL	$111.62 - $139.44 $3.78 Million - $4.72 Million	-33,824 Reduced 24.02%	107,011 $14.6 Million
Q3 2024 Nov 13, 2024	BUY	$114.58 - $153.15 $2.04 Million - $2.73 Million	17,837 Added 14.5%	140,835 $16.2 Million
Q2 2024 Aug 13, 2024	BUY	$130.86 - $143.19 $7.48 Million - $8.18 Million	57,128 Added 86.73%	122,998 $16.9 Million
Q1 2024 May 13, 2024	SELL	$130.4 - $143.74 $1.39 Million - $1.53 Million	-10,679 Reduced 13.95%	65,870 $9.08 Million
Q4 2023 Feb 13, 2024	SELL	$106.07 - $132.76 $524,091 - $655,967	-4,941 Reduced 6.06%	76,549 $10.1 Million
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $709,004 - $883,051	-7,541 Reduced 8.47%	81,490 $9.17 Million
Q2 2023 Aug 11, 2023	BUY	$89.53 - $104.87 $1.62 Million - $1.89 Million	18,043 Added 25.42%	89,031 $8.4 Million
Q1 2023 May 11, 2023	BUY	$94.11 - $123.02 $219,652 - $287,128	2,334 Added 3.4%	70,988 $7.19 Million
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $376,188 - $447,886	3,525 Added 5.41%	68,654 $8.2 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $2.28 Million - $2.67 Million	24,727 Added 61.2%	65,129 $6.92 Million
Q2 2022 Aug 12, 2022	SELL	$75.79 - $100.07 $1.48 Million - $1.95 Million	-19,494 Reduced 32.55%	40,402 $3.94 Million
Q1 2022 May 13, 2022	SELL	$72.45 - $94.81 $456,724 - $597,682	-6,304 Reduced 9.52%	59,896 $5.62 Million
Q4 2021 Feb 10, 2022	BUY	$79.65 - $106.22 $2.71 Million - $3.61 Million	33,986 Added 105.5%	66,200 $5.64 Million
Q3 2021 Nov 10, 2021	BUY	$86.18 - $99.03 $496,741 - $570,808	5,764 Added 21.79%	32,214 $3.09 Million
Q2 2021 Aug 10, 2021	SELL	$89.43 - $102.27 $705,244 - $806,501	-7,886 Reduced 22.97%	26,450 $2.57 Million
Q1 2021 May 10, 2021	BUY	$87.57 - $119.4 $2.1 Million - $2.87 Million	24,002 Added 232.26%	34,336 $3.34 Million
Q4 2020 Feb 10, 2021	SELL	$86.91 - $108.33 $819,735 - $1.02 Million	-9,432 Reduced 47.72%	10,334 $991,000
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $828,995 - $1.17 Million	8,621 Added 77.35%	19,766 $1.9 Million
Q2 2020 Aug 07, 2020	BUY	$85.09 - $130.36 $584,057 - $894,791	6,864 Added 160.34%	11,145 $1.36 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $2.35 Million - $3.56 Million	-31,334 Reduced 87.98%	4,281 $371,000
Q4 2019 Feb 10, 2020	SELL	$86.8 - $118.57 $2.75 Million - $3.75 Million	-31,629 Reduced 47.04%	35,615 $3.83 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $697,801 - $844,987	8,325 Added 14.13%	67,244 $6.06 Million
Q2 2019 Aug 09, 2019	SELL	$72.24 - $91.27 $405,338 - $512,115	-5,611 Reduced 8.7%	58,919 $4.98 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $4.47 Million - $5.91 Million	64,530 New	64,530 $5.69 Million

Others Institutions Holding NBIX

# of Institutions

718

Shares Held

102M

Call Options Held

228K

Put Options Held

336K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account

Rafferty Asset Management, LLC Neurocrine Biosciences Inc Transaction History